Arbutus Biopharma (ABUS) Operating Margin (2016 - 2025)
Historic Operating Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1636.86%.
- Arbutus Biopharma's Operating Margin fell 356700.0% to 1636.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 320.44%, marking a year-over-year increase of 9126200.0%. This contributed to the annual value of 1236.74% for FY2024, which is 8062000.0% down from last year.
- According to the latest figures from Q3 2025, Arbutus Biopharma's Operating Margin is 1636.86%, which was down 356700.0% from 13.86% recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Operating Margin ranged from a high of 13.86% in Q2 2025 and a low of 1636.86% during Q3 2025
- For the 5-year period, Arbutus Biopharma's Operating Margin averaged around 723.96%, with its median value being 648.66% (2021).
- As far as peak fluctuations go, Arbutus Biopharma's Operating Margin tumbled by -11383800bps in 2024, and later skyrocketed by 12643200bps in 2025.
- Quarter analysis of 5 years shows Arbutus Biopharma's Operating Margin stood at 648.66% in 2021, then skyrocketed by 44bps to 361.28% in 2022, then tumbled by -168bps to 967.23% in 2023, then increased by 8bps to 885.2% in 2024, then crashed by -85bps to 1636.86% in 2025.
- Its Operating Margin was 1636.86% in Q3 2025, compared to 13.86% in Q2 2025 and 1456.86% in Q1 2025.